MATRIXX Software Teams Up with Hewlett Packard Enterprise to Deliver Real-time 'Monetization-as-a-Service' to CSPs
MATRIXX Software, the global leader in 5G monetization solutions, has collaborated with Hewlett Packard Enterprise (HPE) to bring MATRIXX Digital Commerce to Communications Service Providers (CSPs) via HPE GreenLake, an elastic-as-a-service platform that can run on-premises, at the edge or in a colocation.
MATRIXX Digital Commerce provides a cloud native, real-time converged charging and commerce platform that enables CSPs to compete at web scale. Unique in its offering, MATRIXX makes it possible for CSPs to move quickly, engage digitally and operate more efficiently. Industry-leading service providers such as Dish, Swisscom, Orange, and Three have chosen MATRIXX as their future proof monetization solution as they evolve to cloud native architectures and develop new 5G business models for B2C, B2B and B2B2X.
The demand for and consumption of high speed, high quality network resources and value-added services has skyrocketed this year and will continue to do so as CSPs invest in 5G rollouts. To accelerate the delivery of new services, CSPs are increasingly turning to the cloud to provide the operational agility required to support rapid and continuous development and deployment of new services and offerings. By leveraging HPE GreenLake, service providers benefit from combining the agility and economics of public cloud with the security and performance of on-premises infrastructure required by a mission critical, high volume, low latency application such as MATRIXX Digital Commerce.
“We are excited to be collaborating with MATRIXX Software to deliver their innovative charging and commerce platform,” said Claus Pedersen, VP and GM, Worldwide Telco Infrastructure at HPE. “Delivering MATRIXX as-a-service is another proof point of HPE’s ability to deliver business advantage to CSPs whilst freeing them from the Capex investments and the daily cost and complexity of managing these applications on-premises. We deliver these advantages on HPE’s proven carrier-grade infrastructure whilst enabling our customers to flexibly scale the capacity to their business needs.”
“We are thrilled to be collaborating with HPE to bring disruptive propositions to the highly competitive CSP market,” said Marc Price, CTO, MATRIXX Software, “Together, MATRIXX and HPE deliver state-of-the-art solutions that enable CSPs to focus on commercial and technology innovations so they can quickly capture the imagination of their customers and increase market share.”
HPE GreenLake Cloud Services provide customers with a powerful foundation to drive digital transformation through an elastic-as-a-service platform that can run on-premises, at the edge, or in a colocation facility. HPE GreenLake combines the simplicity and agility of the cloud with the governance, compliance, and visibility that comes with hybrid IT. HPE GreenLake offers a range of cloud services that accelerate innovation, including cloud services for compute, container management, data protection, HPC, machine learning operations, networking, SAP HANA, and storage, VDI, and VMs. The HPE GreenLake Cloud Services business is rapidly growing with over $4 billion USD in total contract value, over 700 partners selling HPE GreenLake, and more than 1000 customers in all industry sectors and sizes including Fortune 500 companies.
About MATRIXX Software
MATRIXX Software is the global leader in 5G monetization for the communications industry. Serving many of the world’s largest operator groups, regional carriers, and emerging digital service providers, MATRIXX delivers a cloud native digital commerce solution that enables unmatched commercial and operational agility. Unifying IT & networks, MATRIXX delivers a network-grade converged charging system (CCS) enabling efficient hyper-scaling of infrastructure to support consumer services, wholesale and enterprise marketplaces. Through its relentless commitment to product excellence and customer success, MATRIXX empowers businesses to harness network assets and business agility to succeed at web scale.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005101/en/
Contact information
Jennifer Kyriakakis
mediainquiry@matrixx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom